Switch theme
Sign up to access all valuation multiples
Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.
2014
n/a
LTM Revenue n/a
LTM EBITDA n/a
$201M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nextbiomedical has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Nextbiomedical achieved revenue of $6.5M and an EBITDA of $2.6M.
Nextbiomedical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nextbiomedical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $3.3M | $6.5M | XXX | XXX | XXX |
| Gross Profit | $0.2M | $1.4M | XXX | XXX | XXX |
| Gross Margin | 6% | 22% | XXX | XXX | XXX |
| EBITDA | -$4.4M | $2.6M | XXX | XXX | XXX |
| EBITDA Margin | -133% | 41% | XXX | XXX | XXX |
| Net Profit | -$3.8M | -$5.1M | XXX | XXX | XXX |
| Net Margin | -114% | -79% | XXX | XXX | XXX |
| Net Debt | $5.4M | $5.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Nextbiomedical's stock price is KRW 40250 (or $27).
Nextbiomedical has current market cap of KRW 325B (or $222M), and EV of KRW 295B (or $201M).
See Nextbiomedical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $201M | $222M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Nextbiomedical has market cap of $222M and EV of $201M.
Nextbiomedical's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Nextbiomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Nextbiomedical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $201M | XXX | XXX | XXX |
| EV/Revenue | 30.9x | XXX | XXX | XXX |
| EV/EBITDA | 76.1x | XXX | XXX | XXX |
| P/E | 113.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -179.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNextbiomedical's NTM/LTM revenue growth is n/a
Nextbiomedical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Nextbiomedical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Nextbiomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Nextbiomedical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 95% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 41% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -160% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 69% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 98% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanoform | XXX | XXX | XXX | XXX | XXX | XXX |
| Peptron | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nextbiomedical acquired XXX companies to date.
Last acquisition by Nextbiomedical was XXXXXXXX, XXXXX XXXXX XXXXXX . Nextbiomedical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Nextbiomedical founded? | Nextbiomedical was founded in 2014. |
| Where is Nextbiomedical headquartered? | Nextbiomedical is headquartered in South Korea. |
| Is Nextbiomedical publicy listed? | Yes, Nextbiomedical is a public company listed on KRX. |
| What is the stock symbol of Nextbiomedical? | Nextbiomedical trades under 389650 ticker. |
| When did Nextbiomedical go public? | Nextbiomedical went public in 2024. |
| Who are competitors of Nextbiomedical? | Similar companies to Nextbiomedical include e.g. LTR Pharma, Starpharma, Schott Pharma, Nanoform. |
| What is the current market cap of Nextbiomedical? | Nextbiomedical's current market cap is $222M |
| What is the current revenue growth of Nextbiomedical? | Nextbiomedical revenue growth between 2023 and 2024 was 95%. |
| Is Nextbiomedical profitable? | Yes, Nextbiomedical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
